| Name | Title | Contact Details |
|---|---|---|
Scott McMillan |
Chief Technical Officer | Profile |
Our Story Kiniksa’s goal is to build a fully-integrated biopharmaceutical company. Our management team and employees are focused on advancing a portfolio of immune-modulating, clinical-stage product candidates that target underserved conditions and off...
Remix Therapeutics is a biotechnology company developing novel small molecule therapies designed to reprogram RNA processing and treat disease in entirely new ways.
XyloCor Therapeutics is a biopharmaceutical company focused on the development of novel gene therapy for unmet needs in advanced coronary artery disease. In the United States, coronary artery disease is a leading cause of death and disability. The Company`s lead product candidate, XC001, is in clinical development to investigate use for patients with refractory angina for which there are no treatment options. XyloCor also has a secondary product, XC002, in discovery stage, being developed for the treatment of patients with cardiac tissue damage from heart attacks. Co founded by Ronald Crystal, MD, and Todd Rosengart, MD, XyloCor has a licensing agreement with Weill Cornell Medicine for the worldwide rights to develop, manufacture and commercialize XC001.
Lifetree Pain Clinic is a Salt Lake City, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Akonni Biosystems is a Frederick, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.